Novel MRI methods for assessment of GBM
Research type
Research Study
Full title
Novel MRI methods to understand the mechanism of treatment response and resistance in Glioblastoma multiforme (GBM): An MRI study.
IRAS ID
322014
Contact name
Harish Poptani
Contact email
Sponsor organisation
University of Liverpool
Duration of Study in the UK
3 years, 5 months, 31 days
Research summary
GBM is an agressive brain cancer with poor prognosis despite treatment. Maximal surgical resection followed by radiotherapy along with temozolomide is the mainstay treatment for glioblastomas (GBM) despite recent steps towards a more personalised approach. However, the exact mechanisms through which treatment leads to response, resistance or impact on the normal brain tissue remain poorly understood. Standard MRI methods are excellent for detecting the location and size of tumours. Clinical MRI-based response assessment in neuro-oncology (RANO) criteria are used to assess response, however, the current standard MRI scans are unable to differentiate between recurrence and treatment response in up to one third of cases. This can lead to delays in management and a lost window of opportunity to change treatments. The growth, aggressiveness and treatment resistance of GBM depends on a complex interplay between tumour microenvironment and cell metabolism. An ability to dissect the relative contributions of physiological and metabolic factors non-invasively, would be very useful for evaluating therapeutic response and mechanisms of therapy resistance. In this prospective clinical study, we will apply our advanced MRI protocol in a longitudinal study to assess its potential in differentiating treatment response from failure.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
23/NE/0114
Date of REC Opinion
5 Jul 2023
REC opinion
Further Information Favourable Opinion